AbbVie Inc

AbbVie boosts Skyrizi advertising, outpacing J&J’s Tremfya, and sponsors a high‑profile ESMO Asia oncology symposium—showing strategic focus on psoriasis, ovarian cancer ADCs, and expanding dermatologic research.

AbbVie’s latest migraine and immunology data reveal how the company plans to win EU payers, beat CGRP rivals, and protect revenue before Humira’s patent ends.

AbbVie’s new atogepant data and protein‑degradation pipeline highlight its bid to dominate migraine and unlock untapped markets, while it navigates generic threats to Restasis and expands its precision‑medicine portfolio.

AbbVie’s Skyrizi gets Canada’s public drug plan approval, boosting ulcerative colitis access and revenue prospects for the specialty pharma leader.

AbbVie’s rising earnings outlook, robust oncology pipeline and strategic ADC focus highlight its growth in targeted cancer therapies and long‑term investor confidence.

AbbVie’s first FDA‑approved bispecific antibody, EPKINLY + R2, opens a new front for relapsed follicular lymphoma—offering clinical gains, market edge and $300‑$500 m potential upside.

AbbVie’s musculoskeletal oncology focus, strong cash flow and strategic M&A plans are driving bullish analyst sentiment and higher price targets despite looming patent cliffs.

AbbVie Inc. navigates market volatility and product expansion, with recent FDA approvals poised to influence its revenue trajectory and market positioning, while the company’s diversified portfolio and strategic focus on precision medicine and patie…

AbbVie Inc. has announced a downward revision to its earnings guidance due to a significant investment in research and development and strategic acquisitions, but the company’s diversified revenue streams and promising pipeline of new products, incl…

AbbVie Inc. has revised its earnings guidance downward due to a $2.7 billion research and development charge and market access challenges, but its long-term pipeline and strategic partnerships remain promising for the biotechnology firm.